Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 177 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Viagra (sildenafil citrate) Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Sildenafil on Choroidal Thickness in AMD

NCT01830790
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study

NCT03154476
View directory record Official record
Conditions
Cirrhosis, Congenital Heart Disease
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 10, 2026, 8:04 AM EDT
Terminated Not applicable Interventional Results available

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929
View directory record Official record
Conditions
Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions
Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sildenafil Citrate on Insulin Resistance in African American

NCT01334554
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 10, 2026, 8:04 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure

NCT00793338
View directory record Official record
Conditions
Heart Failure
Interventions
Sildenafil
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 10, 2026, 8:04 AM EDT
Recruiting Phase 2 Interventional

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

NCT05201144
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypertension
Interventions
Sildenafil Oral Suspension, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 10, 2026, 8:04 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00940901
View directory record Official record
Conditions
Sickle Cell Disease, Priapism
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Results available

Study of Effects of Sildenafil on Patients With Fontan Heart Circulation

NCT01815502
View directory record Official record
Conditions
Single Ventricle Heart Disease After Fontan Surgery
Interventions
Cardiac catheterization
Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sildenafil Exercise: Role of PDE5 Inhibition

NCT04039087
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil 40mg oral capsule, Placebo Oral capsule
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
9 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.

NCT00795938
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 10, 2026, 8:04 AM EDT
Terminated Phase 4 Interventional Results available

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

NCT03945643
View directory record Official record
Conditions
Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 10, 2026, 8:04 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury

NCT04820881
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 10, 2026, 8:04 AM EDT
Completed No phase listed Observational

Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)

NCT01181284
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 10, 2026, 8:04 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

NCT06800092
View directory record Official record
Conditions
Cancer
Interventions
Sildenafil
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Early Phase 1 Interventional

Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction

NCT03229512
View directory record Official record
Conditions
Hand Foot Skin Reaction
Interventions
Sildenafil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 2 Interventional

Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

NCT00640458
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Sildenafil 100 mg, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204
View directory record Official record
Conditions
Improve Endothelial Function and Decrease Vascular Stenosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 10, 2026, 8:04 AM EDT
Terminated No phase listed Observational

Pharmacokinetics and Pharmacdynamics of Sildenafil

NCT00718185
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Obtain blood specimens
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 10, 2026, 8:04 AM EDT
Not listed Phase 3 Interventional

Sildenafil in US Heart Failure Patients (SilHF-US)

NCT03460470
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Sildenafil, Placebo oral capsule
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 10, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults

NCT01986673
View directory record Official record
Conditions
Healthy
Interventions
5% Sildenafil Cream (SST-6006), Oral Sildenafil 50 mg
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 10, 2026, 8:04 AM EDT